Artiva Biotherapeutics

ARTV

Market cap $152M

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA.

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation.

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis.

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL). The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings: Poster ID: 440 AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases Poster Session: Health Services and Barriers to Access Date / Time:  Thursday, February 5, 2026, at 6:30 pm MST Author: Nicholas Veomett, Ph.D.

Artiva Biotherapeutics is working on NK cell-based immunotherapy to treat autoimmune disease. Their lead project is an unmodified, preserved NK product that seeks to address challenges posed for CAR T-cell therapies. Early trial data in B-cell lymphoma suggests activity, and ARTV is guiding a data readout in the near term for autoimmune disease.

32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were treated in community rheumatology trial sites with no specialized oncology oversight, demonstrating the feasibility of administering this regimen outside the hospital setting No cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) Consistent and complete B-cell depletion was observed in all patients with autoimmune disease treated with AlloNK + mAb by Day 13 of treatment, consistent with the experience for AlloNK + mAb in B-cell driven lymphoma Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration (FDA) regulatory interactions to align on pivotal trial design for AlloNK in refractory rheumatoid arthritis (RA) in the first half of 2026 Management will host a webcast today at 8:00 a.m. ET SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced positive initial safety and translational data from ongoing clinical trials of AlloNK® (also known as AB-101) in combination with rituximab or obinutuzumab for the treatment of autoimmune disease.

Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, the first known therapy within the emerging deep B-cell depletion category to receive this designation in RA Company to host webcast later this morning to discuss initial safety and translational data from clinical trials evaluating AlloNK in combination with anti-CD20 monoclonal antibodies across autoimmune diseases; presentation to also include outpatient feasibility and tolerability observations Initial clinical response data in refractory RA expected in the first half of 2026, with FDA discussions planned to align on potential pivotal trial design in refractory RA Cash runway into Q2 2027, with cash, cash equivalents, and investments of $123.0 million as of September 30, 2025 SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the third quarter ended September 30, 2025, and provided recent business updates. “During the third quarter, we continued to execute on our mission to deliver accessible, scalable immunotherapies for autoimmune disease.

The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy, highlighting a favorable tolerability profile observed to date and the feasibility of patient management in outpatient rheumatology clinics Initial translational data highlighting uniform, consistent, deep B-cell depletion supporting AlloNK's intended mechanism of action SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will host a virtual event discussing initial safety and translational data for AlloNK® in combination with anti-CD20 antibodies across autoimmune diseases.

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) --  Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate at the following investor conferences: TD Cowen's Immunology & Inflammation Summit (Virtual) - fireside chat on Wednesday, November 12, 2025, at 11:30 a.m. ET 2025 Jefferies Global Healthcare Conference in London - fireside chat on Tuesday, November 18, 2025, at 12:00 p.m.